EDP Sciences logo
Web of Conferences logo
Search
Menu
All issues Volume 271 (2021) E3S Web Conf., 271 (2021) 01037 References
Open Access
Issue
E3S Web Conf.
Volume 271, 2021
2021 2nd International Academic Conference on Energy Conservation, Environmental Protection and Energy Science (ICEPE 2021)
Article Number 01037
Number of page(s) 9
Section Energy Development and Utilization and Energy Storage Technology Application
DOI https://doi.org/10.1051/e3sconf/202127101037
Published online 15 June 2021
  1. Sharma, Alok, et al. “Exploring status of emergency drugs and vaccine development in Covid-19 pandemic: an update.” VirusDisease (2021): 1–13. [PubMed] [Google Scholar]
  2. Hong, Ki Ho, et al. “Guidelines for laboratory diagnosis of coronavirus disease 2019 (COVID-19) in Korea.” Annals of laboratory medicine 40.5 (2020): 351–360. [CrossRef] [PubMed] [Google Scholar]
  3. Hilleman, M. R. “Recombinant vector vaccines in vaccinology.” Developments in biological standardization 82 (1994): 3–20. [PubMed] [Google Scholar]
  4. Liu, Margaret A. “Immunologic basis of vaccine vectors.” Immunity 33.4 (2010): 504–515. [CrossRef] [Google Scholar]
  5. Schlake, Thomas, et al. “Developing mRNA-vaccine technologies.” RNA biology 9. 11 (2012): 1319–1330. [CrossRef] [PubMed] [Google Scholar]
  6. Zhang, Na-Na, et al. “A thermostable mRNA vaccine against COVID-19.” Cell 182.5 (2020): 1271–1283. [CrossRef] [Google Scholar]
  7. Fotin-Mleczek, Mariola, et al. “Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.” Journal of immunotherapy 34.1 (2011): 1–15. [CrossRef] [Google Scholar]
  8. Maruggi, Giulietta, et al. “mRNA as a transformative technology for vaccine development to control infectious diseases.” Molecular Therapy 27.4 (2019): 757–772. [CrossRef] [Google Scholar]
  9. Maruggi, Giulietta, et al. “Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens.” Vaccine 35.2 (2017): 361–368. [CrossRef] [Google Scholar]
  10. Liang, Frank, et al. “Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques.” Molecular Therapy 25.12 (2017): 2635–2647. [CrossRef] [Google Scholar]
  11. Locht, Camille. “Vaccines against COVID-19.” Anaesthesia, critical care & pain medicine (2020). [Google Scholar]
  12. Pardi, Norbert, et al. “Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses.” Journal of Experimental Medicine 215.6 (2018): 1571–1588. [CrossRef] [Google Scholar]
  13. Sahin, Ugur, Katalin Karikó, and Özlem Türeci. “mRNA-based therapeutics—developing a new class of drugs.” Nature reviews Drug discovery 13.10 (2014): 759–780. [CrossRef] [PubMed] [Google Scholar]
  14. Tai, Wanbo, et al. “A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection.” Virology 499 (2016): 375–382. [CrossRef] [PubMed] [Google Scholar]
  15. Mulligan, Mark J., et al. “Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.” Nature 586.7830 (2020): 589–593. [CrossRef] [Google Scholar]
  16. Jackson, Lisa A., et al. “An mRNA vaccine against SARS-CoV-2—preliminary report.” New England Journal of Medicine (2020). [Google Scholar]
  17. Anderson, Evan J., et al. “Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults.” New England Journal of Medicine 383.25 (2020): 2427–2438. [CrossRef] [Google Scholar]
  18. Polack, Fernando P., et al. “Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.” New England Journal of Medicine 383.27 (2020): 2603–2615. [CrossRef] [PubMed] [Google Scholar]
  19. Baden, Lindsey R., et al. “Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.” New England Journal of Medicine 384.5 (2021): 403–416. [CrossRef] [PubMed] [Google Scholar]
  20. Palacios, Ricardo, et al. “Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac– PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.” Trials 21.1 (2020): 1–3. [Google Scholar]
  21. Gao, Qiang, et al. “Development of an inactivated vaccine candidate for SARS-CoV-2.” Science 369.6499 (2020): 77–81. [CrossRef] [PubMed] [Google Scholar]
  22. Sharma, Omna, et al. “A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.” Frontiers in immunology 11 (2020): 2413. [Google Scholar]
  23. Xia, Shengli, et al. “Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials.” Jama 324.10 (2020): 951–960. [CrossRef] [Google Scholar]
  24. Zhang, Chao, and Dongming Zhou. “Adenoviral vector-based strategies against infectious disease and cancer.” Human vaccines & immunotherapeutics 12.8 (2016): 2064–2074. [CrossRef] [Google Scholar]
  25. Khuri, Fadlo R., et al. “A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.” Nature medicine 6.8 (2000): 879–885. [CrossRef] [PubMed] [Google Scholar]
  26. Ugai, Hideyo, et al. “Adenoviral protein V promotes a process of viral assembly through nucleophosmin 1.” Virology 432.2 (2012): 283–295. [CrossRef] [Google Scholar]
  27. Crawford-Miksza, Leta, and David P. Schnurr. “Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues.” Journal of virology 70.3 (1996): 1836–1844. [CrossRef] [Google Scholar]
  28. Liu, Hongrong, et al. “Atomic structure of human adenovirus by cryo-EM reveals interactions among protein networks.” Science 329.5995 (2010): 10381043. [Google Scholar]
  29. Polo, John M., and Thomas W. Dubensky Jr. “Virus-based vectors for human vaccine applications.” Drug discovery today 7.13 (2002): 719–727. [CrossRef] [Google Scholar]
  30. Barouch, Dan H., and Gary J. Nabel. “Adenovirus vector-based vaccines for human immunodeficiency virus type 1.” Human gene therapy 16.2 (2005): 149156. [Google Scholar]
  31. Takafuji, Ernest T., et al. “Simultaneous administration of live, enteric-coated adenovirus types 4, 7, and 21 vaccines: safety and immunogenicity.” Journal of Infectious Diseases 140.1 (1979): 48–53. [CrossRef] [Google Scholar]
  32. Schagen, Frederik H.E., et al. “Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion.” Critical reviews in oncology/hematology 50.1 (2004): 51–70. [CrossRef] [Google Scholar]
  33. Zhu, Feng-Cai, et al. “Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.” The Lancet 396.10249 (2020): 479–488. [CrossRef] [Google Scholar]
  34. Ramasamy, Maheshi N., et al. “Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.” The Lancet 396.10267 (2020): 1979–1993. [CrossRef] [Google Scholar]
  35. Francis, Michael James. “Recent advances in vaccine technologies.” The Veterinary Clinics of North America. Small Animal Practice 48.2 (2018): 231. [CrossRef] [Google Scholar]
  36. Marciani, Dante J., et al. “Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats.” Vaccine 9.2 (1991): 89–96. [CrossRef] [Google Scholar]
  37. Cregg, J. M., et al. “High–level expression and efficient assembly of hepatitis B surface antigen in the methylotrophic yeast, Pichia pastoris.” Bio/technology 5.5 (1987): 479–485. [Google Scholar]
  38. Uttenthal, Âse, et al. “Classical swine fever (CSF) marker vaccine: Trial I. Challenge studies in weaner pigs.” Veterinary Microbiology 83.2 (2001): 85–106. [CrossRef] [Google Scholar]
  39. Hua, Rong-Hong, et al. “Generation and characterization of a new mammalian cell line continuously expressing virus-like particles of Japanese encephalitis virus for a subunit vaccine candidate.” BMC biotechnology 14.1 (2014): 1–9. [Google Scholar]
  40. Keech, Cheryl, et al. “Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine.” New England Journal of Medicine 383.24 (2020): 2320–2332. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.